Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)

Market Cap	3.40B
Revenue (ttm)	163.44M
Net Income (ttm)	-79.83M
Shares Out	414.69M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,723,000
Average Volume	17,966,427
Open	8.00
Previous Close	8.30
Day's Range	8.00 - 8.32
52-Week Range	4.60 - 40.98
Beta	0.33
RSI	51.52
Earnings Date	Jul 31, 2025

About SHE:002693

Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Haikou, the People’s Republic of China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 605
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002693

Financial Performance

In 2024, SHE:002693's revenue was 174.21 million, a decrease of -26.16% compared to the previous year's 235.93 million. Losses were -78.30 million, 54.3% more than in 2023.